Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care

Executive Summary

Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.


Related Content

Hoping Drugs Take Root, Alder Raises $38 Million Round
H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat
Medimmune Bets on Pain: Why The Large Molecule Specialist Thinks It Can Win
Alder Obtains First Milestone Under BMS Deal, Advances Own Program In Cancer Supportive Care
Physicians Have Bigger Stake In Patients' Total Care Under Medicare ACOs
Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder
Amgen Expands Inflammation Pipeline With Avidia Purchase


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts